Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
13C3 caffeine is a stable isotope-labeled form of caffeine (1,3,7-trimethylxanthine) where three carbon atoms are replaced with the carbon-13 isotope. It is primarily utilized in clinical research as a metabolic probe or diagnostic marker to investigate physiological processes such as gastric emptying, intestinal absorption, and liver function. In the context of biopharmaceutical research at the Universität Greifswald, it is used as a reference marker to evaluate the performance of oral delivery systems, specifically to track the disintegration and absorption kinetics of enteric-coated and permeation-enhancing formulations for vitamins like cyanocobalamin (B12) and thiamine (B1). As a chemical entity, caffeine acts as a non-selective adenosine receptor antagonist and a competitive phosphodiesterase inhibitor, though its application in this specific trial context is for its pharmacokinetic properties as a tracer rather than for therapeutic effect.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 13C3 caffeine.